Thomas Prebet, MD, PhD
Associate Professor Adjunct
Research & Publications
Biography
News
Research Summary
Specialized terms: Leukemia, myelodysplasia, epigenetics
Research Interests
Hematology; Leukemia; Myelodysplastic Syndromes
Clinical Trials
| Conditions | Study Title |
|---|---|
| Multiple Myeloma | A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma. |
| Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's Lymphoma | Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release |
| Leukemia, not otherwise specified; Leukemia, other | A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia |
| Leukemia, not otherwise specified; Leukemia, other | Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease |